Agf Investments LLC Nektar Therapeutics Transaction History

Agf Investments LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 30, 2019	SELL	$31.0 - $36.3 $115,630 - $135,399	-3,730 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$31.58 - $46.35 $536,386 - $787,254	-16,985 Reduced 81.99%	3,730 $125,000
Q4 2018 Feb 08, 2019	BUY	$30.43 - $56.65 $596,245 - $1.11 Million	19,594 Added 1747.9%	20,715 $681,000
Q3 2018 Nov 09, 2018	BUY	$46.46 - $68.49 $17,236 - $25,409	371 Added 49.47%	1,121 $63,000
Q3 2018 Nov 07, 2018	BUY	$46.46 - $68.49 $696 - $1,027	15 Added 2.04%	750 $28,000
Q2 2018 Aug 13, 2018	BUY	$46.25 - $104.45 $17,158 - $38,750	371 Added 101.92%	735 $35,000
Q1 2018 May 04, 2018	SELL	$57.4 - $108.44 $34,554 - $65,280	-602 Reduced 62.32%	364 $31,000
Q4 2017 Feb 07, 2018	BUY	$23.02 - $60.5 $22,237 - $58,443	966	966 $56,000

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $197M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Agf Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Agf Investments LLC with notifications on news.